Poliomyelitis clinical trials
The registry lists 274 studies for Poliomyelitis across more than 10 countries. 18 are recruiting or about to start. 145 of them are mainly about Poliomyelitis (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-10. Counting its narrower condition Postpoliomyelitis Syndrome too: 295 studies, 21 open.
Get an email when these change. Save the Poliomyelitis studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Who runs them
Sanofi Pasteur, a Sanofi Company (45) · GlaxoSmithKline (44) · Sanofi (15) · Sinovac Biotech Co., Ltd (15) · Centers for Disease Control and Prevention (14) · Aga Khan University (13) · Fidec Corporation (10) · PATH (8)
What is being tested here
Drugs under test in Poliomyelitis studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted
Coming up
Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.
All 8, phase 3 first
- Mar 2027A Study to Evaluate the Mucosal Intestinal Immunity to Poliovirus Type-2 of nOPV2 at Birth Dose in Healthy IPV Vaccinated Infants · Phase 3 · Fidec Corporation
- Nov 2026Safety and Immunogenicity of a Recombinant Poliomyelitis Vaccine (rPV) in Comparison With IPOL Vaccine in Healthy Adults · Serum Institute of India Pvt. Ltd.
- Dec 2026Study of Co-administered (Types 1 & 2) Novel Oral Poliomyelitis Vaccines Evaluation · PATH
- Dec 2026the Five-year Antibody Persistence After Immunization With IPV, MMR and HepA-L Vaccines · China National Biotec Group Company Limited
- Mar 2027Effects of Virtual Walking on Chronic Pain and Psychological Distress for Individuals With Severe Mobility Impairment · The Hong Kong Polytechnic University
- Mar 2027Study of a Novel Type 3 Oral Poliomyelitis Vaccine in Panama · PATH
- Aug 2027A Phase I/II Clinical Trial of the Diphtheria, Tetanus, Acellular Component Pertussis and Sabin Inactivated Poliomyelitis Vaccine Adsorbed · Institute of Medical Biology, Chinese Academy of Medical Sciences
- Oct 2027Safety and Immunogenicity of a Combined Diphtheria, Tetanus, Whole Cell Pertussis, Hepatitis B, Recombinant Poliomyelitis and Haemophilus Influenzae Type b (Hib) Vaccine (SIIPL DTwP-HepB-rPV-Hib) · Serum Institute of India Pvt. Ltd.
Who these studies take
Of the 10 Poliomyelitis studies recruiting now, 0 (0%) set no upper age limit and 10 (100%) stop at 75 or younger. 9 (90%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 10 (100%) take healthy volunteers.
| Age | Women | Men |
|---|---|---|
| 10 | 2 (20%) | 2 (20%) |
| 18 | 3 (30%) | 3 (30%) |
| 30 | 3 (30%) | 3 (30%) |
| 40 | 3 (30%) | 3 (30%) |
| 50 | 2 (20%) | 2 (20%) |
| 65 | 0 (0%) | 0 (0%) |
| 75 | 0 (0%) | 0 (0%) |
| 85 | 0 (0%) | 0 (0%) |
Across all 274 studies, recruiting or not: 91% stop at 75 or younger and 90% at 65; 87% take children; 1% are for women only and 1% for men only; 91% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
How long Poliomyelitis studies take
Of 44 phase 3 interventional studies under Poliomyelitis, half reached primary completion within 12 months of starting, counting those still running.
| Start to primary completion | Every sponsor | Industry | Non-industry |
|---|---|---|---|
| Phase 1 | 3 mo2–18 · 12 studies | — | — |
| Phase 2 | 12 mo5–38 · 12 studies | — | — |
| Phase 3 | 12 mo7–21 · 44 studies | 15 mo7–21 · 35 studies | — |
| Phase 4 | 13 mo7–25 · 30 studies | — | — |
| Interventional, no phase | 19 mo12–22 · 16 studies | — | — |
Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out
What changed recently
From the registry's own updates since Oct 12, 2026.
Newly registered1
Studies
Recruiting first, then most recently updated. Showing 50 of 274. Browse all 274 → or search them.
- Safety and Immunogenicity of a Combined Diphtheria, Tetanus, Whole Cell Pertussis, Hepatitis B, Recombinant Poliomyelitis and Haemophilus Influenzae Type b (Hib) Vaccine (SIIPL DTwP-HepB-rPV-Hib)RecruitingNCT07855172Phase 1/21 country
- A Phase I/II Clinical Trial of the Diphtheria, Tetanus, Acellular Component Pertussis and Sabin Inactivated Poliomyelitis Vaccine AdsorbedRecruitingNCT07891104Phase 1/21 country
- Safety and Immunogenicity of a Recombinant Poliomyelitis Vaccine (rPV) in Comparison With IPOL Vaccine in Healthy AdultsRecruitingNCT07688369Phase 11 country
- A Study to Evaluate the Mucosal Intestinal Immunity to Poliovirus Type-2 of nOPV2 at Birth Dose in Healthy IPV Vaccinated InfantsRecruitingNCT07010822Phase 31 country
- Study of BK1803 in Healthy InfantsNot yet recruitingNCT07793513Phase 31 country
- Study of a Novel Type 3 Oral Poliomyelitis Vaccine in PanamaRecruitingNCT05654467Phase 21 country
- Phase IV Clinical Study of Sequential Vaccination of Sabin Strain and Wild Strain Inactivated Poliovirus VaccineRecruitingNCT07457060Phase 41 country
- Phase IV Clinical Study of sIPV Administration in Adolescent and Adult PopulationsRecruitingNCT07354269Phase 41 country
- the Five-year Antibody Persistence After Immunization With IPV, MMR and HepA-L VaccinesNot yet recruitingNCT073388511 country
- Study of Co-administered (Types 1 & 2) Novel Oral Poliomyelitis Vaccines EvaluationRecruitingNCT06895486Phase 21 country
- Study of Trivalent and Bivalent (Types 1 & 2) Novel Oral Poliomyelitis VaccinesRecruitingNCT06137664Phase 1/21 country
- Study of Concomitant Administration of the sIPV and DTaP or MMRNot yet recruitingNCT06920069Phase 41 country
- Immunogenicity of Different Primary Immunization Schedules with Inactivated Poliovirus Vaccine (IPV) Plus Pentavalent Vaccine (DTwP-HBV-Hib) or with Hexavalent Vaccine (DTwP-HBV-Hib-IPV)Not yet recruitingNCT06748612Phase 4
- Study to Evaluate the Immunogenicity of LR20062 Compared to Control When Administered Intramuscularly in Healthy Infants At 2, 4, 6 Months of AgeNot yet recruitingNCT06618196Phase 2
- Safety and Immunogenicity of DTaP-IPV/Hib Pentavalent Vaccine in Chinese 2-month-old InfantsRecruitingNCT06605755Not applicable1 country
- Phase IV Study of Concomitant Administration of the sIPV and HepANot yet recruitingNCT06460545Phase 41 country
- Immunogenicity of Novel Oral Poliovirus Vaccine Type 2 (nOPV2), bOPV and IPVNot yet recruitingNCT06114810Phase 4
- A Study to Evaluate Safety and Immunogenicity of APV006 in Healthy AdultsNot yet recruitingNCT05952596Phase 1
- Clinical Study of the Tolerability, Reactogenicity, and Safety of PoliovacSin in Volunteers Aged 18-60 YearsCompletedNCT07914244Phase 11 country
- Study of a Novel Type 1 Oral Poliomyelitis Vaccine in BangladeshCompletedNCT05644184Phase 21 country
- Effects of Virtual Walking on Chronic Pain and Psychological Distress for Individuals With Severe Mobility ImpairmentActive, not recruitingNCT07820618Not applicable1 country
- Study to Evaluate the Immunogenicity and Safety of LBVD(Hexavalent Vaccine), Given to Healthy Infants at Primary SeriesCompletedNCT05457946Phase 2/31 country
- A Phase II/III Study to Evaluate the Immunogenicity, Safety and Lot-to-lot Consistency of LBVD, a Fully Liquid Hexavalent Diphtheria-tetanus-whole Cell Pertussis-hepatitis B-poliovirus-Haemophilus Influenzae Type b Conjugate (DTwP-HepB-IPV-Hib) Vaccine, in Healthy Infants as Primary SeriesActive, not recruitingNCT06947499Phase 2/31 country
- A Study to Evaluate Pharyngeal Immunity to Poliovirus Type-2CompletedNCT05677256Phase 41 country
- A Study to Evaluate the Safety and Immunogenicity of VLP-Polio in Infants and ToddlersActive, not recruitingNCT06577298Phase 1/21 country
- Clinical Study to Assess the Immunogenicity and Safety of Hexavalent Vaccine Containing Reduced Dose IPVCompletedNCT06413121Phase 32 countries
- Evaluation of the Vaccination Coverage of Cirrhotic Patients Followed in the General Hospitals in France in 2021CompletedNCT049393501 country
- The Impact of 'Digital Strolling' on Depression and Quality of Life of People With Severe Mobility ImpairmentCompletedNCT07073144Not applicable1 country
- Booster Dose of sIPV Co-administered With MMR and HepA-I.CompletedNCT06442449Phase 41 country
- Confirmatory Study of BK1310 in Healthy InfantsCompletedNCT03891758Phase 31 country
- Phase III Clinical Trial of Sabin Strain Inactivated Poliovirus Vaccine (Vero Cell)CompletedNCT07297186Phase 31 country
- A Multi-center, Open-labelled, Randomized, Controlled, Extended Phase Ⅲ Clinical Trial of sIPV VaccineCompletedNCT05850364Phase 32 countries
- Study of DTwP-HepB-Hib-IPV (SHAN6™) Vaccine Administered Concomitantly With Routine Pediatric Vaccines to Healthy Infants and Toddlers in ThailandCompletedNCT04429295Phase 31 country
- Study to Evaluate the Immune Response After Booster Vaccination With Tdap-IPV Vaccine (Against Tetanus, Diphtheria, Pertussis and Poliomyelitis) in Children Who Received Different Pertussis Primary Vaccine Regimens in Republic of South AfricaCompletedNCT04300192Phase 41 country
- Study of a Pneumococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Toddlers and InfantsCompletedNCT04398706Phase 24 countries
- High Intensity Functional Training for Individuals With Neurologic Diagnoses and Their Care PartnersCompletedNCT05951985Not applicable1 country
- Comparing Functional Outcomes in Individuals Using Micro-processor Controlled Orthosis Versus Stance Control OrthosisActive, not recruitingNCT02089880Not applicable1 country
- Study to Evaluate Eupolio(IPV)'s Safety, Long-term Protective Effect and Boosting Effect of One Booster Dose in the Three Primary Vaccination Plus Boosting Schedule, and Protective Effect in the Schedule With Bivalent OPV in InfantsCompletedNCT05431933Phase 32 countries
- Assessing Immunogenicity of Intramuscular Sabin Inactivated Poliovirus Vaccine and Non-inferiority of Intradermal Fractional Inactivated Poliovirus VaccineCompletedNCT05460377Phase 41 country
- Sequential Vaccination of Poliomyelitis Vaccine (Vero Cells), Inactivated, Sabin Strains From Different ManufacturersCompletedNCT06346834Phase 41 country
- A Tool Kit to Improve Vaccine Confidence in the PhilippinesActive, not recruitingNCT06218368Not applicable1 country
- A Study to Evaluate Safety and Immunogenicity of Sequential Vaccination of Sabin Inactivated Poliomyelitis Vaccine (Vero Cell) and Live Attenuated Poliomyelitis Vaccine in Healthy 2-month-old InfantsCompletedNCT06752174Phase 31 country
- A Study to Evaluate the Safety and Immunogenicity of Recombinant Trivalent Poliomyelitis Vaccine (Sf-RVN Cell) in Healthy AdultsCompletedNCT06101173Phase 11 country
- Study of Novel Types 1 and 3 Oral Poliomyelitis VaccinesCompletedNCT04529538Phase 11 country
- Immunogenicity nOPV2 With and Without bOPVCompletedNCT04579510Phase 21 country
- Vaccine Campaign Effects on General Hospital Admissions and Mortality Among ChildrenCompletedNCT03460002Phase 41 country
- Study to Evaluate Safety and Immunogenicity of nOPV2 at Different Intervals in InfantsCompletedNCT05033561Phase 31 country
- Comparison of Immune Response Using 2 Vaccination Schedules Using Inactivated Polio VaccineCompletedNCT00137696Not applicable1 country
- Community Engagement and Conditional Incentives to Accelerate PolioCompletedNCT05721274Not applicable1 country
- Safety of Sabin Inactivated Poliovirus Vaccine in Adults, Children and Infants and Lot Consistency Immunogenicity, and Safety of the msIPV in 2 Months Old InfantsCompletedNCT05386810Phase 31 country